Recent Company News

• 11:05 AM ET Jun 14, 2026
  

  Mineralys Therapeutics presents new data on effect of lorundrostat on HF risk biomarkers at ENDO 2026 ($23.62, 0.00)

• 08:33 AM ET Jun 08, 2026
  

  Neurocrine Biosciences presents new data on INGREZZA capsules in individuals with Tardive Dyskinesia ($163.88, 0.00)

• 06:06 AM ET Jun 03, 2026
  

  Mineralys Therapeutics announces repurchase of royalty obligations in Tanabe license agreement and concurrent financing ($28.85, 0.00)

• 11:19 AM ET May 30, 2026
  

  Mineralys Therapeutics presents new data from the phase 3 launch-htn trial of Lorundrostat in participants with hypertension and chronic kidney disease at ESH 2026 ($31.50, 0.00)

• 12:53 AM ET May 28, 2026
  

  Japan Investment Corp looking at selling JSR - Reuters

• 10:05 PM ET May 27, 2026
  

  Mitsubishi Chemical, Accenture establish 81-19 JV RIX Business Partners Corporation

• 12:38 AM ET May 25, 2026
  

  Mitsubishi Chemical considers spin-off of petrochemicals business (¥1096.0000, +68.5)

• 04:10 PM ET May 18, 2026
  

  Neurocrine Biosciences presents real-world data on INGREZZA Capsules in Mild Tardive Dyskinesia ($157.21, 0.00)

• 01:00 AM ET May 13, 2026
  

  Transcript Intelligence: Mitsubishi Chemical Q4 Earnings Guidance

• 01:00 AM ET May 13, 2026
  

  Transcript Intelligence: Mitsubishi Chemical Q4 Earnings Themes